Clinuvel Pharmaceuticals (CUV) Stock Price, News & Analysis

Company Overview

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 124,193 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: 0.36%
• Price Target: N/A
• Consensus Rating: N/A

CUV Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Clinuvel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Clinuvel Pharmaceuticals investors own include Cochlear (COH), CSL (CSL), ResMed (RMD), ARB (ARB), Accent Group (AX1), Corporate Travel Management (CTD) and Mineral Resources (MIN).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:CUV
• CUSIP: N/A
• CIK: N/A
• Web: www.clinuvel.com
• Phone: 61 3 9660 4900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A$0.70
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $35.64 million
• Net Margins: 40.41%
• Pretax Margin: N/A
• Return on Equity: 19.39%
• Return on Assets: 14.29%

Debt

• Debt-to-Equity Ratio: 0.43
• Current Ratio: 8.81
• Quick Ratio: 10.03

Sales & Book Value

• Annual Sales: $88.18 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 19.36
• Book Value: A$4.05 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 50,060,000
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 0.92